Cassava Sciences Inc (SAVA)
25.84
-0.37
(-1.41%)
USD |
NASDAQ |
Nov 04, 16:00
26.00
+0.16
(+0.62%)
After-Hours: 20:00
Cassava Sciences Free Cash Flow: -86.31M for June 30, 2024
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2024 | -86.31M |
| March 31, 2024 | -87.95M |
| December 31, 2023 | -82.44M |
| September 30, 2023 | -81.07M |
| June 30, 2023 | -77.22M |
| March 31, 2023 | -69.88M |
| December 31, 2022 | -80.23M |
| September 30, 2022 | -67.33M |
| June 30, 2022 | -81.43M |
| March 31, 2022 | -74.06M |
| December 31, 2021 | -52.41M |
| September 30, 2021 | -45.50M |
| June 30, 2021 | -10.86M |
| March 31, 2021 | -6.494M |
| December 31, 2020 | -5.382M |
| September 30, 2020 | -4.796M |
| June 30, 2020 | -3.355M |
| March 31, 2020 | -3.104M |
| December 31, 2019 | -2.532M |
| September 30, 2019 | -2.508M |
| June 30, 2019 | -3.214M |
| March 31, 2019 | -3.749M |
| December 31, 2018 | -4.77M |
| September 30, 2018 | -5.642M |
| June 30, 2018 | -6.357M |
| Date | Value |
|---|---|
| March 31, 2018 | -8.428M |
| December 31, 2017 | -8.237M |
| September 30, 2017 | -9.83M |
| June 30, 2017 | -10.54M |
| March 31, 2017 | -10.62M |
| December 31, 2016 | -12.31M |
| September 30, 2016 | -12.83M |
| June 30, 2016 | -12.37M |
| March 31, 2016 | -11.05M |
| December 31, 2015 | -9.248M |
| September 30, 2015 | -8.264M |
| June 30, 2015 | -7.526M |
| March 31, 2015 | -8.169M |
| December 31, 2014 | -9.629M |
| September 30, 2014 | -8.519M |
| June 30, 2014 | -8.666M |
| March 31, 2014 | -7.876M |
| December 31, 2013 | -6.947M |
| September 30, 2013 | -7.347M |
| June 30, 2013 | -6.825M |
| March 31, 2013 | -6.974M |
| December 31, 2012 | -7.171M |
| September 30, 2012 | -6.126M |
| June 30, 2012 | -6.002M |
| March 31, 2012 | -5.599M |
Free Cash Flow Range, Past 5 Years
-87.95M
Minimum
Mar 2024
-2.532M
Maximum
Dec 2019
-48.54M
Average
-67.33M
Median
Sep 2022
Free Cash Flow Benchmarks
| Bristol-Myers Squibb Co | 13.80B |
| Eli Lilly and Co | -2.275B |
| Seelos Therapeutics Inc | -13.27M |
| Biomarin Pharmaceutical Inc | 300.88M |
| EyePoint Pharmaceuticals Inc | -94.36M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -18.24M |
| Cash from Investing (Quarterly) | -0.029M |
| Cash from Financing (Quarterly) | 101.39M |
| Free Cash Flow Per Share (Quarterly) | -0.3954 |
| Free Cash Flow Yield | -7.66% |